cardiovascular disease
Amarin’s Vazkepa accepted by SMC for patients with cardiovascular disease
August 8, 2023Research and Development Cardiology, Vazkepa, cardiovascular disease, pharmaceutical
On 7 August 2023, the Scottish Medicines Consortium (SMC) announced that they had accepted Amarin’s treatment for people with cardiovascular …
Eli Lilly’s Trulicity approved in US to reduce cardiovascular events in type 2 diabetes patients
February 24, 2020Sales and Marketing Eli Lilly, Trulicity, cardiovascular disease, pharma
Eli Lilly’s Trulicity (duraglutide) has been awarded marketing authorisation from the FDA as a therapy to reduce major adverse cardiovascular …
Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD
January 17, 2020Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma
Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …
AstraZeneca’s Farxiga meets Phase 3 primary endpoint in heart failure
August 20, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, cardiovascular disease, farxiga
New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite …
Bayer’s Xarelto combo greenlighted by NICE for reducing CV events in artery disease
August 1, 2019Sales and Marketing NHS, NICE, UK, Xarelto, cardiovascular disease, pharma
NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with …
Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients
February 15, 2019Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes
Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …
China’s NMPA approves Amgen’s Repatha to reduce cardiovascular event risk
January 25, 2019Medical Communications, Sales and Marketing Amgen, China, Repatha, cardiovascular disease, pharma, stroke
Amgen has announced that its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) has secured approval by China’s drug …
Europe expands approved indication of Amgen’s Repatha in cardiovascular disease
May 17, 2018Sales and Marketing Amgen, Repatha, cardiovascular disease, pharma
Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: …
Pfizer taps real world evidence for CVD in new partnership
February 14, 2018Research and Development BC Platforms, Pfizer, biotech, cardiovascular disease, drugs, pharma, pharmaceutical
BC Platforms, a company that focuses on genomic data managements and analysis, has announced that it has partnered with Pfizer …
12% of the UK have hearts ten years older than they are, Public Health England finds
September 4, 2017Research and Development, Sales and Marketing British Heart Foundation, Public Health England, cardiovascular disease, heart attack, heart health, stroke
New findings from Public Health England (PHE)’s Heart Age Test indicate that around 10% of men in the UK are …
Where will the next cardiovascular breakthrough come from?
August 17, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing British Heart Foundation, cardiovascular disease, heart, heart disease, pharma, pharmaceutical
British Heart Foundation’s Jennifer Mitchell, Research Communications Officer, explains the work they are doing to find the next breakthrough treatment …
Battling misinformation on the world’s biggest killer
August 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing cardiovascular disease, cholesterol, healthcare, heart disease, heart failure, medicine, pharma, pharmaceutical
Simon Williams, Head of Communications and Policy at Heart UK, discusses the threat posed by cholesterol in the development of …
Cardiovascular disease expected to place $1 trillion cost burden on US
February 20, 2017Medical Communications, Sales and Marketing cardiovascular disease
A study conducted by RTI International, a non-profit research institute, has warned that the US could have to balance over …
Heart disease drug development is falling
August 30, 2016Manufacturing and Production, Research and Development cardiovascular disease, heart disease, research and development
The number of drugs currently in development to combat heart disease has fallen in the last 20 years, it has …
NICE recommends Sanofi, Amgen cholesterol drugs
May 6, 2016Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
